Intersect ENT, Inc. XENT
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Market cap
- 954.90M
- Revenue (ttm)
- 106.75M
- Profit margin
- -149.54%
- Shares out
- 33.81M
- Forward P/E
- -25.44
- Open
- 28.25
- Previous close
- 28.24
- Day's range
- 28.23 – 28.25
- Beta
- 1.53
- Analysts
- Hold
- Price target
- 28.25 (+0.0%)
- Earnings date
- May 16, 2022
Key statistics
- Enterprise value
- 1.01B
- PEG ratio
- -2.27
- Price / sales
- 8.95
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.70%
- Free cash flow
- -30.55M
- Total cash
- 61.02M
- Total debt
- 144.03M
- Return on equity
- 0.00%
- Short % of float
- 9.59%
- 50-day average
- 27.83
- 200-day average
- 27.38
Analyst view
Consensus: hold
- Strong buy6
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
May 16, 2022
Expected May 16, 2022. Consensus EPS estimate -0.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 16, 2022 | Mar 1, 2022 | -0.34 | — | — | — |
| Mar 8, 2022 | Dec 1, 2021 | -0.30 | — | — | — |
| Nov 2, 2021 | Sep 1, 2021 | -0.42 | — | — | — |
| Aug 6, 2021 | Jun 1, 2021 | -0.42 | — | — | — |
| May 10, 2021 | Mar 1, 2021 | -0.42 | — | — | — |
| Mar 9, 2021 | Dec 1, 2020 | -0.31 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 2021 | SVB Leerink | down | Outperform | Market Perform |
| Aug 10, 2021 | BTIG | down | Buy | Neutral |
| Aug 9, 2021 | Canaccord Genuity | down | Buy | Hold |
| Aug 9, 2021 | Guggenheim | down | Buy | Neutral |
| Jun 24, 2021 | SVB Leerink | up | Market Perform | Outperform |
| May 11, 2021 | SVB Leerink | main | — | Market Perform |
About Intersect ENT, Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- intersectent.com
News
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates 
Orthofix Announces Appointment of Thomas A. West to Board of Directors 
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report? 
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes 
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT 
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc. 
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top 
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
Your note
Sign in to keep a note on XENT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRODERICK PATRICK A | General Counsel | Stock Award(Grant) | Jan 31, 2022 | 47,116 |
| FERNANDEZ REYNA M | Officer | Stock Award(Grant) | Jan 31, 2022 | 31,576 |
| GALLAHUE KIERAN T. | Director | Stock Award(Grant) | Jun 2, 2021 | 37,512 |
| KLINE TERESA L. | Director | Stock Award(Grant) | Jun 2, 2021 | 12,076 |
| KOWALSKI CHRISTINE R | Chief Operating Officer | Stock Award(Grant) | Jan 31, 2021 | 42,269 |
| LUCCHESE CYNTHIA L | Director | Stock Award(Grant) | Jun 2, 2021 | 19,622 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Versor Investments, LP | 9.83% | 3,323,482 | 93.09M | Mar 30, 2022 |
| Versor Investments, LP | 9.83% | 3,323,482 | 93.09M | Mar 30, 2022 |
| Blackrock Inc. | 7.78% | 2,629,605 | 73.66M | Mar 30, 2022 |
| Blackrock Inc. | 7.78% | 2,629,605 | 73.66M | Mar 30, 2022 |
| Magnetar Financial LLC | 7.60% | 2,569,052 | 70.16M | Dec 30, 2021 |
| Magnetar Financial LLC | 7.60% | 2,569,052 | 70.16M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.70% | 912,624 | 24.92M | Dec 30, 2021 |
| iShares Russell 2000 ETF | 2.25% | 760,832 | 20.85M | Jan 30, 2022 |
| Merger Fund, The | 1.53% | 515,698 | 14.08M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 1.36% | 460,996 | 12.59M | Dec 30, 2021 |
| Managed Portfolio Series-Nuance Mid Cap Value Fd | 1.02% | 344,407 | 9.44M | Jan 30, 2022 |
| SPDR (R) Ser Tr-SPDR S&P Health Care Equipment ETF | 0.84% | 283,291 | 7.76M | Jan 30, 2022 |